Joint Stock Company Pharmstandard Sustainability Profile
Joint Stock Company Pharmstandard, headquartered in Russia, is a leading player in the pharmaceutical industry, specialising in the development, production, and distribution of a wide range of medicinal products. Founded in 2003, the company has established itself as a key provider of high-quality pharmaceuticals, with a strong presence in major operational regions across Russia and the CIS. Pharmstandard's core offerings include prescription medications, over-the-counter drugs, and biopharmaceuticals, distinguished by their commitment to innovation and quality. The company has achieved significant milestones, including the introduction of several unique formulations that cater to diverse therapeutic areas. With a robust market position, Pharmstandard is recognised for its contributions to healthcare, making it a trusted name among healthcare professionals and patients alike.
DitchCarbon Score
How does Joint Stock Company Pharmstandard's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Joint Stock Company Pharmstandard's score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Joint Stock Company Pharmstandard's reported carbon emissions
Joint Stock Company Pharmstandard, headquartered in Russia, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing greenhouse gas emissions at this time. As a current subsidiary, Pharmstandard's climate initiatives and emissions data may be influenced by its corporate family, but no specific cascading data from a parent organization has been provided. Consequently, the company appears to be in the early stages of developing a comprehensive climate strategy. In the context of the pharmaceutical industry, where sustainability and climate action are increasingly important, Pharmstandard may need to consider setting measurable targets and participating in initiatives such as the Science Based Targets initiative (SBTi) to align with global climate goals.
How Carbon Intensive is Joint Stock Company Pharmstandard's Industry?
How Carbon Intensive is Joint Stock Company Pharmstandard's Location?
Joint Stock Company Pharmstandard's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Joint Stock Company Pharmstandard has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
